A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)

Trial Profile

A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Cefepime
  • Indications Urinary tract infections
  • Focus Adverse reactions
  • Sponsors AstraZeneca; Pfizer
  • Most Recent Events

    • 25 Oct 2017 Status changed from recruiting to completed.
    • 10 Oct 2017 Planned End Date changed from 2 Oct 2017 to 2 Nov 2017.
    • 10 Oct 2017 Planned primary completion date changed from 2 Oct 2017 to 2 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top